Lipella Pharmaceuticals I... (LIPO)
| Bid | 2.44 |
| Market Cap | 6.24M |
| Revenue (ttm) | 254.05K |
| Net Income (ttm) | -5.02M |
| EPS (ttm) | -4.79 |
| PE Ratio (ttm) | -0.51 |
| Forward PE | -0.15 |
| Analyst | Buy |
| Ask | 2.72 |
| Volume | 10,246 |
| Avg. Volume (20D) | 2,216,095 |
| Open | 2.49 |
| Previous Close | 2.52 |
| Day's Range | 2.44 - 2.53 |
| 52-Week Range | 1.97 - 12.00 |
| Beta | 0.31 |
About LIPO
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Th...
Analyst Forecast
According to 1 analyst ratings, the average rating for LIPO stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 553.06% from the latest price.
Stock Forecasts
1 week ago · prismmediawire.com
Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”Listen: PITTSBURGH, April 23, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc.
1 month ago · prismmediawire.com
Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse PodcastEpisode titled “From Medicine to Biotech Innovation” now available PITTSBURGH, March 31, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”)...
